EAACI Congress 2024 Back

31 May - 03 June 2024 Valencia, Spain

Stefan Zielen

Germany

Stefan Zielen

Sessions

Friday 31 May

12:36 - 12:48 Impact of a 3-tree sublingual immunotherapy liquid formulation in birch family pollen-allergic patients on prevention of disease progression and/or asthma onset

15:36 - 15:48 Epigenetic regulation of exercise-induced bronchoconstriction in patients with and without allergy

Saturday 1 Jun

Slow crippling lung disease in Ataxia telangiectasia: lung function and CT findings

Sunday 2 Jun

Meta-analysis of primary endpoint of PQ Grass field studies with optimized dose and treatment regimen of PQ Grass

Positive outcome of the pivotal Phase III study with PQ Grass, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system

Secondary endpoint profile is strongly supportive for the positive outcome of the pivotal Phase III study with PQ Grass

SAT3-3 Allergy Therapeutics - Setting a new standard for grass subcutaneous immunotherapy Sponsored Sessions Alicante , Channel Alicante

Welcome and Introduction

Q&A session

EAACI Congress 2024 Back

Sessions

Share this pen